ABL1 and acute promyelocytic leukemia: In this domain there are two historical and landmark molecularly well-understood therapies that have been transformative for patients; all trans retinoic acid (ATRA) therapy of acute promyelocytic leukaemia (APL) and BCR:ABL inhibitors in chronic myeloid leukaemia (CML).